Abstract
1385
Objectives To compare the survival and rate of adverse events after radioembolization of unresectable liver metastases from colorectal cancer using glass or resin based yttrium-90 microspheres.
Methods IRB-approved and HIPPA compliant chart review of a cohort of 28 consecutive patients that underwent radioembolization with glass (group 1) or resin based particles (group 2). Mean survival time between the treatment and the patient death was calculated for each group. Follow up imaging examinations were retrospectively reviewed and the mean time between treatment and disease progression in the liver was calculated for each group. Presence and severity of adverse events including fatigue, nausea and vomiting, abdominal pain, jaundice, cholecystitis and gastritis, deemed to be related to the treatment were record. Two-tailed T-Test was used.
Results 15 patients (mean age 60.1 yrs) underwent glass based treatment and 13 patients (mean age 61.3 yrs) underwent resin based treatment. The mean survival after treatment was 10 months (range 1-38) for group 1 and 16.2 months (range 0-41) for group 2 (p 0.075). The average interval between treatment and disease progression was 2.5 months (range 1-6) for group 1 and 2.6 months (range 0 -10) for group 2 (p 0.74). Group 1 had 3 patients that did not progress, and group 2 had 2 patients that did not progress. There were no deaths deemed to be a direct consequence from the treatment. One patient on each group developed severe abdominal pain, but none required surgical intervention. Fatigue was the most common reported symptom (group 1: 53.8%; group 2: 55.5%).
Conclusions Both treatments had similar safety profiles, with no significant difference in the rate of adverse events between the two groups. There was no significant difference in the mean treatment to progression time interval between patients treated with glass and resin yttrium-90 microspheres, although patients treated with resin tended to have greater survival interval.